Adaptive Biotechnologies Corp (ADPT)vsAstraZeneca PLC (AZN)
ADPT
Adaptive Biotechnologies Corp
$16.90
-6.53%
HEALTHCARE · Cap: $2.82B
AZN
AstraZeneca PLC
$185.95
-1.94%
HEALTHCARE · Cap: $282.69B
Smart Verdict
WallStSmart Research — data-driven comparison
AstraZeneca PLC generates 20360% more annual revenue ($60.44B vs $295.41M). AZN leads profitability with a 17.2% profit margin vs -16.8%. AZN earns a higher WallStSmart Score of 64/100 (C+).
ADPT
Avoid30
out of 100
Grade: F
AZN
Buy64
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+50.3%
Fair Value
$31.45
Current Price
$16.90
$14.55 discount
Margin of Safety
+8.2%
Fair Value
$194.77
Current Price
$185.95
$8.82 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Revenue surging 35.1% year-over-year
Mega-cap, among the largest globally
Every $100 of equity generates 22 in profit
Strong operational efficiency at 27.9%
Generating 1.8B in free cash flow
Areas to Watch
Trading at 12.4x book value
0.0% earnings growth
ROE of -23.0% — below average capital efficiency
Negative free cash flow — burning cash
Moderate valuation
Distress zone — elevated risk
Comparative Analysis Report
WallStSmart ResearchBull Case : ADPT
The strongest argument for ADPT centers on Revenue Growth. Revenue growth of 35.1% demonstrates continued momentum.
Bull Case : AZN
The strongest argument for AZN centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 17.2% and operating margin at 27.9%. Revenue growth of 12.5% demonstrates continued momentum.
Bear Case : ADPT
The primary concerns for ADPT are Price/Book, EPS Growth, Return on Equity.
Bear Case : AZN
The primary concerns for AZN are P/E Ratio, Altman Z-Score.
Key Dynamics to Monitor
ADPT profiles as a hypergrowth stock while AZN is a mature play — different risk/reward profiles.
ADPT carries more volatility with a beta of 2.15 — expect wider price swings.
ADPT is growing revenue faster at 35.1% — sustainability is the question.
AZN generates stronger free cash flow (1.8B), providing more financial flexibility.
Bottom Line
AZN scores higher overall (64/100 vs 30/100), backed by strong 17.2% margins and 12.5% revenue growth. ADPT offers better value entry with a 50.3% margin of safety. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Adaptive Biotechnologies Corp
HEALTHCARE · DIAGNOSTICS & RESEARCH · USA
Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company is headquartered in Seattle, Washington.
Visit Website →AstraZeneca PLC
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.
Compare with Other DIAGNOSTICS & RESEARCH Stocks
Want to dig deeper into these stocks?